BEGIN:VCALENDAR
VERSION:2.0
PRODID:https://www.umh.de/
BEGIN:VEVENT
DTSTAMP:20240429T233004Z
UID:event2004202366302d7cb62008.35917192
DTSTART:20230419T220000Z
DTEND:20230422T215959Z
LOCATION:Steintor-Varieté Halle (Saale)\, Am Steintor 10\, 06112 Halle\, Foyer
SUMMARY:Tumor Immunology meets Oncology (TIMO) XVII 2023 Halle
DESCRIPTION:The meeting „Tumor Immunology meets Oncology (TIMO)“ has established
 itself as an outstanding platform for exchange between scientists\,
 clinicians and junior staff and as one of the leading European conferences
 in the field of tumor immunology. From 20-22 April 2023\, the meeting will
 happen for the 17th time at the Steintor Varieté Halle (Saale).\nThe
 symposium takes place over three days and begins with a workshop that
 enables young scientists to present their own data in a short lecture. The
 latest methods and techniques in the field of tumor treatment will also be
 presented. The accompanying poster exhibition facilitates discussion of
 further projects and the establishment of new cooperations. Following the
 workshop\, we will award prizes for the three best lectures and posters.
 The scientific program will be rounded off with a networking evening on
 Friday allowing the discussion of projects and experiments in a relaxed
 atmosphere.\nOn the following two days\, the established and renowned
 scientists will have their say. An overview:\nProf. Hinrich Abken
 (Regensburg\, GER)\nCARs become CHIC: cytokine help intensified CAR T
 cells\nProf. Achim Aigner (Leipzig\, GER)\nNanoparticle-based delivery of
 nucleic acids in tumor and immune cells\nProf. Michael Bachmann (Dresden\,
 GER)\nModular Immunotargeting\nProf. Mascha Binder (Basel\, CH)\nBiomarkers
 in IO trials for solid tumors\nProf. Martin Bornhäuser (Dresden\,
 GER)\nCurrent limitations of immunotherapeutic approaches in AML\nProf.
 Vincenzo Bronte (Padova\, ITA)\nNeutrophil extracellular traps restrain
 anti-tumor T cell activity in pancreatic cancer\nDr. Aitziber Buqué
 Martinez (New York\, USA)\nConditioning TME metabolism to improve radiation
 and endocrine-based therapies\nProf. Angus Dalgleish (London\,
 GBR)\nHarvesting the anti-tumour activity of Vγ9Vδ2 T cells in cancer
 immunotherapy\nProf. Sandra Demaria (New York\, USA)\nImmunotherapy
 targeting different immune compartments in combination with radiation
 therapy induces regression of resistant tumors\nDr. Noel de Miranda
 (Leiden\, NL)\nNew players in colorectal cancer immunity: beyond
 (conventional) T cells\nProf. Bernard Fox (Portland\, USA)\nPeptidomics and
 immunotherapy\nProf. Lorenzo Galluzzi (New York\, USA)\nHarnessing
 radiotherapy to unlock the full potential of cancer immunotherapy\nProf.
 Stefan Glück (Miami\, USA)\nPatients are waiting - the promise of immune
 oncology for 2023 and beyond\nProf. Hubert Hackl (Innsbruck\,
 AUT)\nImmunogenomic analyses reveal vulnerability for combination
 immunotherapy in ovarian cancer\nProf. Stefano Indraccolo (Padova\,
 ITA)\nLiquid biopsy to track therapeutic and adverse effects of
 immunotherapy in lung cancer patients\nProf. Markus Maeurer (Lissabon\,
 PRT)\nCellular immune responses directed against pancreatic cancer: the
 trilogy of AB-\, GD- and MAIT-T-cells\nProf. Michele Maio (Siena\,
 ITA)\nEpigenetics and melanoma\nProf. Ofer Mandelboim (Jerusalem\,
 ISR)\nFusubacterium nucleatum: from tooth to tumors\nProf. Sergio Rutella
 (Nottingham\, GBR)\nClinical implications of T cell dysfunctional states in
 acute myeloid leukaemia\nProf. Barbara Seliger (Halle\, Brandenburg\,
 GER)\nNon-coding RNAs as regulators of the tumor immune escape and
 therapeutic  targets in tumors\nStina Wickström (Stockhom\,
 SWE)\nImproving ACT therapy through combination with a DC tumor vaccine and
 protecting NK cells and T cells against oxidative stress\nProf. Qing Yang
 (Fudan\, CHN)\nRole and clinical relevance of indoleamine 2‘3‘
 dioxygenase in tumors\nThe meeting is made possible by the great commitment
 of the members of the Institute of Medical Immunology of the Martin Luther
 University Halle-Wittenberg\, the support of the German Society of
 Immunology (DGfI)\, the Society of Immunotherapy in Cancer (SITC) and its
 staff as well as the commitment of numerous sponsors. We are looking
 forward to another exciting event in 2023!\nSchedule of the meeting
 2023\nThursday\, 20th of April 2023:\nWORKSHOP\nStart: 12.00 a.m.\nEnd:   
 5.30 p.m.\nPoster Session: 05.30-7.00 p.m.\nSpeakers: students\, postdocs\,
 young professionals\, spin offs\nFriday\, 21st of April 2023:\nMAIN
 SYMPOSIUM\nStart: 8.30 a.m.\nEnd:    6.00 p.m.\nSpeakers: professionals\,
 clinicians\, researchers\nNetworking event/ dinner for ALL: 8.00 p.m. in
 Halle (Saale)\, Steintor-Varieté \nSaturday\, 22nd of April 2023:\nMAIN
 SYMPOSIUM\nStart: 8.30 a.m.\nEnd:    1.00 p.m.\nSpeakers: professionals\,
 clinicians\, researchers\nRegistration fee:\n300 € (regular) 200 € (Ph
 students) 100 € (external BSc/MSc students and employees of the MLU)    
 0 € (students of the MLU)\nPlease register via the registration link at
 the homepage of the German Society of
 Immunology:\nhttps://dgfi.org/arbeitskreise/ak-tumorimmunologie/meeting/\nN
 ews will follow!
END:VEVENT
END:VCALENDAR